Second report on pharma patents published by EC
In 2009, the European Commission (EC) published a report on the pharmaceuticals sector. It found that increasing numbers of patent settlement agreements were being concluded between originator and...
View Article“The Patent Cliff – Lipitor goes over the Edge”
As the largest ever number of patents protecting the pharmaceutical industry’s most profitable “blockbuster” drugs are set to expire, for India and China it’s going to be a very merry Christmas and an...
View ArticleGovernment proposes change in law to make UK a better place to carry out drug...
The UK Government would like to change the law to make the UK a more amenable place to carry out clinical trials. There is an exemption from breach of patented pharmaceutical products when the use is...
View ArticleProtect Your Position – Bristol-Myers buys Inhibitex for $2.5 billion
With the Patent Cliff looming and the lack of new drugs to fill the void keeping big Pharma bosses awake at night, we are seeing new strategies emerging in an attempt to off see the gloom and doom...
View ArticleA small step for Cipla, a giant step for Generic Kind
The Indian generics company, Cipla, has grabbed the headlines not once but twice over the last few weeks for pushing the generic cause onwards and leaving big pharma feeling the effects in its wake....
View ArticleSupplementary Protection Certificates – High Court refers questions to be...
Actavis v Sanofi, High Court To the frustration of the parties and judge alike, the High Court has decided to refer particular questions on the interpretation of Article 3(a),(c) and (d) of the...
View ArticleSupplemental Protection Certificates and the “First Authorisation” Rule
AstraZeneca AB v Comptroller-General of Patents, Designs and Trade Marks, High Court; Case numbers CH/2012/0232 and CH/2012/0489 The High Court has once again decided to refer questions of...
View ArticlePatent Problems for Genentech as follow-on patents found invalid by High Court
Hospira UK Ltd v Genentech Inc, High Court The High Court has found two patents related to the breast cancer drug, Herceptin, to be invalid. Hospira issued the claim in the High Court in order to clear...
View Article
